Company:  VICAL INC (VICL)
Form Type:  10-Q
Filing Date:  5/2/2014 
CIK:  0000819050 
Address:  10390 PACIFIC CENTER COURT
.
 
City, State, Zip:  SAN DIEGO, California 92121-4340 
Telephone:  858-646-1100 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$1.29  
Change: 
0.04 (3.20%)  
Trade Time: 
Jun 22  
Market Cap: 
$28.14M
Trade VICL now with 

© 2018  
Description of Business
We research and develop biopharmaceutical products, including those based on our patented DNA delivery technologies, for the prevention and treatment of serious or life-threatening diseases. We currently have three active development programs in the area of infectious disease comprised of: * An ongoing Phase 2 trial of our HSV-2 therapeutic vaccine, VCL-HB01, to treat patients with symptomatic genital herpes infection. The vaccine candidate is currently being evaluated in a Phase 2 study in adult subjects, 18 to 50 years of age who are randomized 2:1 to receive either vaccine or placebo. Recruitment of 261 subjects at 15 U.S. clinical sites was completed in April 2017 and dosing was completed in July 2017.
Register and access this filing in:     
  FORM 10-Q
    PART I. FINANCIAL INFORMATION
      ITEM 1. FINANCIAL STATEMENTS
        BALANCE SHEET
        INCOME STATEMENT
        CASH FLOW
        NOTES TO FINANCIAL STATEMENTS
          BALANCE SHEET
      ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL ...
      ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT ...
      ITEM 4. CONTROLS AND PROCEDURES
    PART II. OTHER INFORMATION
      ITEM 1. LEGAL PROCEEDINGS
      ITEM 1A. RISK FACTORS
      ITEM 6. EXHIBITS
    SIGNATURE
  EXHIBIT 10.1
  EXHIBIT 31.1
    CERTIFICATION
  EXHIBIT 32.1
    CERTIFICATION PURSUANT TO